Global contract development and manufacturing organization (CDMO), Recipharm, has unveiled an investment and capacity expansion at its facility in Israel. This investment will support customers’ growing demand for cGMP clinical supply of active pharma ingredients (API) and intermediates and is part of an integrated plan to enhance Recipharm’s offering in drug substances services.   The investment will see the implementation of a full GMP chemical unit including a number of brand-new R&D labo...